Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardiAQ Valve Technologies

This article was originally published in Start Up

Executive Summary

Today, mitral valve repair and replacement procedures involve opening the chest and stopping the heart. Hence, many patients who might otherwise benefit from therapy are excluded because they are either too ill or not ill enough to justify the risk. A percutaneous mitral valve replacement system in development from CardiAQ Valve Technologies intends to significantly reduce that risk by using a catheter to deliver a new mitral valve.
Advertisement

Related Content

Start-Up Previews (06/2009)
Start-Up Previews (06/2009)
Percutaneous Heart Valve Technology: The Mitral Challenge
NeoChord Inc.
Evalve, Mitralign Deals: Heart Valves Draw New Device Investors
Evalve: Leading the Valve Revolution

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel